Literature DB >> 25239802

Alternative splicing impairs soluble guanylyl cyclase function in aortic aneurysm.

Emil Martin1, Eva Golunski1, Susan T Laing1, Anthony L Estrera2, Iraida G Sharina3.   

Abstract

Nitric oxide (NO) receptor soluble guanylyl cyclase (sGC) is a key regulator of several important vascular functions and is important for maintaining cardiovascular homeostasis and vascular plasticity. Diminished sGC expression and function contributes to pathogenesis of several cardiovascular diseases. However, the processes that control sGC expression in vascular tissue remain poorly understood. Previous work in animal and cell models revealed the complexity of alternative splicing of sGC genes and demonstrated its importance in modulation of sGC function. The aim of this study was to examine the role of alternative splicing of α1 and β1 sGC in healthy and diseased human vascular tissue. Our study found a variety of α1 and β1 sGC splice forms expressed in human aorta. Their composition and abundance were different between samples of aortic tissue removed during surgical repair of aortic aneurysm and samples of aortas without aneurysm. Aortas with aneurysm demonstrated decreased sGC activity, which correlated with increased expression of dysfunctional sGC splice variants. In addition, the expression of 55-kDa oxidation-resistant α1 isoform B sGC (α1-IsoB) was significantly lower in aortic samples with aneurysm. The α1-IsoB splice variant was demonstrated to support sGC activity in aortic lysates. Together, our results suggest that alternative splicing contributes to diminished sGC function in vascular dysfunction. Precise understanding of sGC splicing regulation could help to design new therapeutic interventions and to personalize sGC-targeting therapies in treatments of vascular disease.
Copyright © 2014 the American Physiological Society.

Entities:  

Keywords:  alternative splicing; aorta; nitric oxide; soluble guanylyl cyclase

Mesh:

Substances:

Year:  2014        PMID: 25239802      PMCID: PMC4255009          DOI: 10.1152/ajpheart.00222.2014

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  49 in total

1.  Regional and age-dependent expression of the nitric oxide receptor, soluble guanylyl cyclase, in the human brain.

Authors:  C Ibarra; P I Nedvetsky; M Gerlach; P Riederer; H H Schmidt
Journal:  Brain Res       Date:  2001-07-13       Impact factor: 3.252

Review 2.  Genetic basis of thoracic aortic aneurysms and dissections: focus on smooth muscle cell contractile dysfunction.

Authors:  Dianna M Milewicz; Dong-Chuan Guo; Van Tran-Fadulu; Andrea L Lafont; Christina L Papke; Sakiko Inamoto; Carrie S Kwartler; Hariyadarshi Pannu
Journal:  Annu Rev Genomics Hum Genet       Date:  2008       Impact factor: 8.929

Review 3.  RNA splicing manipulation: strategies to modify gene expression for a variety of therapeutic outcomes.

Authors:  Steve D Wilton; Susan Fletcher
Journal:  Curr Gene Ther       Date:  2011-08       Impact factor: 4.391

Review 4.  RNA splicing in regulation of nitric oxide receptor soluble guanylyl cyclase.

Authors:  Iraida G Sharina; Gilbert J Cote; Emil Martin; Marie-Francoise Doursout; Ferid Murad
Journal:  Nitric Oxide       Date:  2011-08-16       Impact factor: 4.427

5.  Expression of nitric oxide-sensitive guanylyl cyclase subunits in human corpus cavernosum.

Authors:  S Behrends; A Steenpass; H Porst; H Scholz
Journal:  Biochem Pharmacol       Date:  2000-03-15       Impact factor: 5.858

6.  Ascending thoracic aorta dimension and outcomes in acute type B dissection (from the International Registry of Acute Aortic Dissection [IRAD]).

Authors:  Anna M Booher; Eric M Isselbacher; Christoph A Nienaber; James B Froehlich; Santi Trimarchi; Jeanna V Cooper; Stefanos Demertzis; Vijay S Ramanath; James L Januzzi; Kevin M Harris; Patrick T O'Gara; Thoralf M Sundt; Reed E Pyeritz; Kim A Eagle
Journal:  Am J Cardiol       Date:  2011-01-15       Impact factor: 2.778

7.  Cobinamides are novel coactivators of nitric oxide receptor that target soluble guanylyl cyclase catalytic domain.

Authors:  Iraida Sharina; Michael Sobolevsky; Marie-Francoise Doursout; Dorota Gryko; Emil Martin
Journal:  J Pharmacol Exp Ther       Date:  2011-12-13       Impact factor: 4.030

8.  Interleukin-1 beta and lipopolysaccharide decrease soluble guanylyl cyclase in brain cells: NO-independent destabilization of protein and NO-dependent decrease of mRNA.

Authors:  Carlos E Pedraza; María Antonia Baltrons; Michael T Heneka; Agustina García
Journal:  J Neuroimmunol       Date:  2003-11       Impact factor: 3.478

9.  Nitric oxide sensitive-guanylyl cyclase subunit expression changes during estrous cycle in anterior pituitary glands.

Authors:  Jimena P Cabilla; Sonia A Ronchetti; Silvana I Nudler; Eliana A Miler; Fernanda A Quinteros; Beatriz H Duvilanski
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-01-13       Impact factor: 4.310

10.  FK409, a new nitric-oxide donor, suppresses smooth muscle proliferation in the rat model of balloon angioplasty.

Authors:  J Seki; M Nishio; Y Kato; Y Motoyama; K Yoshida
Journal:  Atherosclerosis       Date:  1995-09       Impact factor: 5.162

View more
  9 in total

Review 1.  Role of sGC-dependent NO signalling and myocardial infarction risk.

Authors:  Jana Wobst; Thorsten Kessler; Tan An Dang; Jeanette Erdmann; Heribert Schunkert
Journal:  J Mol Med (Berl)       Date:  2015-03-04       Impact factor: 4.599

2.  The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies.

Authors:  I G Sharina; M Sobolevsky; A Papakyriakou; N Rukoyatkina; G A Spyroulias; S Gambaryan; E Martin
Journal:  Br J Pharmacol       Date:  2015-02-10       Impact factor: 8.739

Review 3.  Structure and Activation of Soluble Guanylyl Cyclase, the Nitric Oxide Sensor.

Authors:  William R Montfort; Jessica A Wales; Andrzej Weichsel
Journal:  Antioxid Redox Signal       Date:  2016-04-26       Impact factor: 8.401

4.  Disrupted nitric oxide signaling due to GUCY1A3 mutations increases risk for moyamoya disease, achalasia and hypertension.

Authors:  S Wallace; D-C Guo; E Regalado; L Mellor-Crummey; M Bamshad; D A Nickerson; R Dauser; N Hanchard; R Marom; E Martin; V Berka; I Sharina; V Ganesan; D Saunders; S A Morris; D M Milewicz
Journal:  Clin Genet       Date:  2016-02-18       Impact factor: 4.438

5.  Higher susceptibility to heme oxidation and lower protein stability of the rare α1C517Yβ1 sGC variant associated with moyamoya syndrome.

Authors:  Iraida Sharina; Karina Lezgyieva; Yekaterina Krutsenko; Emil Martin
Journal:  Biochem Pharmacol       Date:  2021-02-08       Impact factor: 5.858

Review 6.  The emerging role of alternative splicing in senescence and aging.

Authors:  Mathieu Deschênes; Benoit Chabot
Journal:  Aging Cell       Date:  2017-07-13       Impact factor: 9.304

Review 7.  Maturation, inactivation, and recovery mechanisms of soluble guanylyl cyclase.

Authors:  Dennis J Stuehr; Saurav Misra; Yue Dai; Arnab Ghosh
Journal:  J Biol Chem       Date:  2021-01-26       Impact factor: 5.157

8.  Profiling of the full-length transcriptome in abdominal aortic aneurysm using nanopore-based direct RNA sequencing.

Authors:  Hai Xin; Xingqiang He; Jun Li; Xiaomei Guan; Xukui Liu; Yuewei Wang; Liyuan Niu; Deqiang Qiu; Xuejun Wu; Haofu Wang
Journal:  Open Biol       Date:  2022-02-02       Impact factor: 6.411

9.  Alteration of the soluble guanylate cyclase system in coronary arteries of high cholesterol diet-fed rabbits.

Authors:  Masashi Tawa; Katsuya Nakano; Yuka Yamashita; Qiang He; Takayoshi Masuoka; Tomio Okamura; Takaharu Ishibashi
Journal:  Pharmacol Res Perspect       Date:  2021-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.